Brief: Trinity Biotech Subsidiary, Primus Corporation Receives FDA Warning Letter
17/08/2020 16:02
Aug 17 (Reuters) - Trinity Biotech PLC TRIB.O :
* TRINITY BIOTECH SUBSIDIARY, PRIMUS CORPORATION RECEIVES
FDA
WARNING LETTER
* TRINITY BIOTECH - PRIMUS CORP GOT WARNING LETTER FROM FDA
FOLLOWING INSPECTION OF KANSAS CITY, MISSOURI MANUFACTURING
FACILITY THAT TOOK PLACE IN JAN. 2020
* TRINITY BIOTECH - ISSUES IDENTIFIED IN FDA WARNING LETTER
PRIMARILY RELATE TO COMPANY'S ULTRA2 PRODUCT RANGE
Source text for Eikon: ID:nGNX7WC2Y3
Further company coverage: TRIB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trinity Biotech
See all newsNASDAQ RESUMED AT 12:18 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:13 PM
Brief: Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
Brief: Trinity Biotech’S Trinovium Subsidiary Agrees To Collaborate With Echelon Data Centres To Develop Advanced Liquid Cooling Solutions For Ai Infrastructure
NASDAQ RESUMED AT 09:00 AM